载脂蛋白E抗体

载脂蛋白E抗体Quantity size:

0.2ml

Concentration:

1mg/ml   Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. ApoE exists in three major isoforms; E2, E3, and E4,载脂蛋白E抗体 which differ from one another by a single amino-acid substitution. Compared with E3 and E4, E2 exhibits the lowest receptor binding affinity. Defects in ApoE are a cause of hyperlipoproteinemia type III due to increased plasma cholesterol and triglycerides levels which are the consequence of impaired clearance of chylomicron and VLDL remnants.
Summary: Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2.载脂蛋白E抗体 Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq, Jul 2008].

Also known as:

载脂蛋白E抗体Apolipoprotein E precursor; AD2; Alzheimer disease 2; Apo E; ApoE; APOEA; ApolipoproteinE; Apolipoprotein-E; Apoprotein; MGC1571; Apo E2; ApoE2; APOE 2; Apolipoprotein E2; LDLCQ5; LPG; APOE_HUMAN; Apo-E.

Specificity:

●

Rabbit Polyclonal IgG, affinity purified by Protein A.

●

Reacts with: Mouse, Rat, .

●

Immunogen: KLH conjugated synthetic peptide derived from mouse Apo E.

●

Predicted Molecular Weight: 32kDa.

载脂蛋白E抗体Storage:

Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500   
Not yet tested in other applications. 
Optimal working dilutions must be determined by the end user.

kl226Mu01胃脂酶(LIPF)多克隆抗体Polyclonal Antibody to Likle, Gastric (LIPF)

kl226Ra01胃脂酶(LIPF)多克隆抗体Polyclonal Antibody to Likle, Gastric (LIPF)

kl226Po01胃脂酶(LIPF)多克隆抗体Polyclonal Antibody to Likle, Gastric (LIPF)

kl469Hu01内皮脂肪酶(LIPG)多克隆抗体Polyclonal Antibody to Likle, Endothelial (LIPG)

kl469Mu01内皮脂肪酶(LIPG)多克隆抗体Polyclonal Antibody to Likle, Endothelial (LIPG)

kl469Ra01内皮脂肪酶(LIPG)多克隆抗体Polyclonal Antibody to Likle, Endothelial (LIPG)

kl176Hu01脂肪酶I(LIPI)多克隆抗体Polyclonal Antibody to Likle I (LIPI)

kl176Mu01脂肪酶I(LIPI)多克隆抗体Polyclonal Antibody to Likle I (LIPI)

kl176Ra01脂肪酶I(LIPI)多克隆抗体Polyclonal Antibody to Likle I (LIPI)

kl175Hu01脂肪酶H(LIPH)多克隆抗体Polyclonal Antibody to Likle H (LIPH)

kl175Mu01脂肪酶H(LIPH)多克隆抗体Polyclonal Antibody to Likle H (LIPH)